Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
Current price $2.55
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Nov 19, 25 | Maxim Group | downgrade | Buy | Hold |
| Sep 8, 25 | D. Boral Capital | downgrade | Buy | Hold |
| Aug 26, 25 | D. Boral Capital | maintain | Buy | Buy |
| Aug 18, 25 | D. Boral Capital | maintain | Buy | Buy |
| Aug 6, 25 | D. Boral Capital | maintain | Buy | Buy |
| Aug 4, 25 | D. Boral Capital | maintain | Buy | Buy |
| Jul 8, 25 | D. Boral Capital |
| upgrade |
| Hold |
| Buy |
| Jun 11, 25 | D. Boral Capital | downgrade | Buy | Hold |
| Jun 6, 25 | D. Boral Capital | maintain | Buy | Buy |
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 30.26 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 2.40 | Oscillator | Buy |
| Williams %R (14) | -94.44 | Oscillator | Buy |
| MACD (12, 26, 9) | -0.67 (Hist 0.03) | Oscillator | Buy |
| Average Directional Index (14) | 38.51 (+DI 37.6 / -DI 21.4) | Trend | Strong Buy |
| EMA 20 | 3.26 | MA | Strong Sell |
| SMA 20 | 3.21 | MA | Strong Sell |
| EMA 50 | 4.94 | MA | Strong Sell |
| SMA 50 | 4.72 | MA | Strong Sell |
| SMA 200 | 19.41 | MA | Strong Sell |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Jul 17, 26 | Matsui Connie | director | A-Award | 136 @ $1.15 | $156 |
| Jul 17, 26 | Blayney Douglas | director | A-Award | 136 @ $1.15 | $156 |
| Jul 17, 26 | Reyes Gregory | director | A-Award | 136 @ $1.15 | $156 |
| Jul 17, 26 | Emanuele Robert Martin | director | A-Award | 136 @ $1.15 | $156 |
| Jul 17, 26 | Kelly Steven | director | A-Award | 136 @ $1.15 | $156 |
| Jul 17, 26 | Favorito Tamara A | director | A-Award | 136 @ $1.15 | $156 |
| Jan 30, 26 | Matsui Connie | director | A-Award | 292 @ $1.71 | $499 |
| Jan 30, 26 | Blayney Douglas | director | A-Award | 292 @ $1.71 | $499 |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 8-K | Oct 9, 2026 | 2026-10-09 17:15:59 | View |
| 8-K | Aug 27, 2026 | 2026-08-27 08:30:31 | View |
| 10-Q/A | Aug 20, 2026 | 2026-08-20 16:30:22 | View |
| SC 13G/A | Aug 14, 2026 | 2026-08-14 10:01:06 | View |
| SC 13G/A | Aug 13, 2026 | 2026-08-13 10:16:09 | View |
| 10-Q | Aug 12, 2026 | 2026-08-12 16:32:27 | View |
| 4 | Jul 21, 2026 | 2026-07-21 18:31:46 | View |
| 4 | Jul 21, 2026 | 2026-07-21 18:29:50 | View |
| 4 | Jul 21, 2026 | 2026-07-21 18:28:39 | View |
| 4 | Jul 21, 2026 | 2026-07-21 18:27:11 | View |
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | ARTL | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -0.0x | -14.1x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -0.0x | EPS est. -88.56 | Discount |
| Price / Book | 0.2x | 6.2x | Discount |
| Price / Sales | — | — | n/a |
| EV / EBITDA | -0.4x | -4.3x | Discount |
| Return on equity | -519.1% | — | Weak |
| Gross margin | 0.0% | 0.0% | n/a |
| Debt / Equity | 0.01 | -0.10 | Conservative |
| Piotroski / Altman Z | 2/9 | Z -16.79 | Distress |
Discounted cash flow model
Stock news · updated daily
Artelo Biosciences, Inc. (NASDAQ: ARTL - Get Free Report) saw a large growth in short interest in the month of September. As of September 30th, there was short interest totaling 46,160 shares, a growth of 104.7% from the September 15th total of 22,550 shares. Based on an average trading volume of 2,494,370 shares, the days-to-cover ratio
Presentation to feature results from first clinical study of ART26.12 and highlight the potential of FABP5 inhibition across multiple indications
Artelo Biosciences, Inc. (NASDAQ: ARTL - Get Free Report) saw a large decrease in short interest during the month of September. As of September 15th, there was short interest totaling 22,550 shares, a decrease of 37.2% from the August 31st total of 35,918 shares. Based on an average trading volume of 45,211 shares, the short-interest ratio
As reported, ART27.13 produced approximately 40% weight loss in combination with semaglutide and approximately 20% as monotherapy, comparable to semaglutide, in obese mice over four weeks
Once-daily, oral ART27.13 reduced body weight by approximately 20% in obese mice, matching the weight loss achieved with semaglutide, the active ingredient in Ozempic ® and Wegovy ®
Artelo Biosciences, Inc. (NASDAQ: ARTL - Get Free Report) saw a significant decline in short interest in the month of August. As of August 14th, there was short interest totaling 85,320 shares, a decline of 36.9% from the July 30th total of 135,122 shares. Currently, 1.9% of the shares of the company are sold short. Based
Shares Expected to Begin Trading on a Split-Adjusted Basis on August 31, 2026 Shares Expected to Begin Trading on a Split-Adjusted Basis on August 31, 2026
SOLANA BEACH, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced that the Japanese Patent Office has issued a notification of allowance with a Decision to Grant for the Company's patent application covering the intended commercial formulation of ART27.13, Artelo's peripherally selective dual cannabinoid agonist currently being evaluated in two Phase 2 clinical trials.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 12, 2026 | -6.48 | -8.01 | Miss -23.6% | — |
| May 14, 2026 | -0.78 | -4.00 | Miss -412.8% | — |
| Feb 24, 2026 | -4.71 | -6.66 | Miss -41.4% | — |
| Nov 12, 2025 | -2.46 | -11.91 | Miss -384.1% | — |
| Aug 12, 2025 | -12.57 | -16.83 | Miss -33.9% | — |
| May 13, 2025 | -2.40 | -12.96 | Miss -440.1% | — |